Search results
Results from the WOW.Com Content Network
Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. [10] It contains nivolumab , a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab , a lymphocyte activation gene-3 (LAG-3) blocking antibody. [ 10 ]
The trial compared Opdivo + Yervoy to standard-of-care chemotherapy as a first-line treatment for unresectable or metastatic urothelial carcinoma patients whose tumor cells express PD-L1 ≥1%.
Opdivo, which is one of the top sellers for Bristol Myers, brought in $9.01 billion in revenue in 2023, while Yervoy earned $2.24 billion in the same period. (Reporting by Puyaan Singh; Editing by ...
Bristol Myers (BMY) gets FDA approval for the Opdivo and Yervoy combination for the treatment of HCC.
Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. [2] This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal ...
The European Commission approved Bristol Myers Squibb & Co's (NYSE: BMY) fixed-dose combination of Opdualag (nivolumab and relatlimab) for melanoma patients aged 12 years and above. Melanoma is a ...
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction. [8]
Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.